Figure 7.

Increased levels of 12-LOX in ESCC patients are associated with poor prognoses. (A) (a) Immunohistochemical scores of 12-LOX of all samples. The samples above the red line (score = 0.77) were in the high-expression group, and the rest were in the low-expression group; (b) box plots of the high-expression and low-expression groups. (B) Pearson correlation analysis in ESCC tissues showed that 12-LOX protein levels positively correlated with CCL5 in ESCC tissues (r = 0.549; P < 0.001). Immunohistochemical scores of 12-LOX are on the x-axis, and immunohistochemical scores of CCL5 are on the y-axis. (C–E) Expression of 12-LOX (C), CCL5 (D), and CD68 (E) in the low-expression group (a) and high-expression group (b). Their high expression levels were all associated with poor survival prognoses in the K-M curve (c) (12-LOX, P < 0.001; CCL5, P = 0.03; CD68, P < 0.001). (F) ROC curve and AUC of 12-LOX, differentiation, N stage, and T stage: (a) 12-LOX, AUC = 0.673; (b) differentiation, AUC = 0.641; (c) N stage, AUC = 0.660; and (d) T stage, AUC = 0.701.

Abbreviations: AUC, area under the curve; ESCC, esophageal squamous cell carcinoma; ROC, receiver operating characteristic.